Inclusion Criteria

Inclusion Criteria

Patients must have:

- HIV seropositivity.

- Biopsy-proven mucocutaneous Kaposi's sarcoma with fewer than 50 skin lesions and
measurable disease.

- No active opportunistic infection. NOTE:

- Patients with CD4 count >= 200 cells/mm3 must have no prior opportunistic infection,
as well as no active opportunistic infection.

- Life expectancy of at least 24 weeks.

- Stable weight (+/- 2 kg) by 28 days prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Other active malignancies (except basal cell carcinoma of the skin and in situ
cervical cancer).

- Known or suspected hypersensitivity to benzodiazepines.

- Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal,
endocrine, hematologic, psychiatric, neurologic, dermatologic, or allergic disease as
determined by the investigator.

- Ongoing diarrhea (> two liquid stools per day).

- Grade 2 or worse signs and symptoms of AIDS Dementia Complex.

- Alteration of mental status that may interfere with study compliance.

Concurrent Medication:

Excluded:

- AZT, ddI, or ddC.

- Experimental antiretrovirals.

- Biologic response modifiers or immunomodulating agents (e.g., interferon).

- Colony stimulating factors (erythropoietin, GM-CSF, G-CSF).

- Ganciclovir.

- Foscarnet.

- H-2 antagonists (cimetidine, ranitidine, famotidine, nizatidine).

- Omeprazole.

- Benzodiazepines.

- Any other investigational compound.

- Ongoing systemic treatment with corticosteroids (other than replacement therapy for
adrenal insufficiency or short-term therapy of no more than 28 days for bronchial
asthma).

- Cytotoxic chemotherapy (systemic and local).

- Drugs known to cause systemic toxicity, if avoidable (e.g., myelosuppressive,
hepatotoxic, nephrotoxic, or neurotoxic drugs).

- Paromomycin sulfate.

- Chronic suppressive therapy for CMV and/or MAI.

Patients with the following prior condition are excluded:

History of serious adverse reactions to benzodiazepines.

Prior Medication:

Excluded:

- Interferons or immune modulators within 4 weeks prior to study entry.

- Prior systemic cytotoxic chemotherapy (patients with CD4 counts >= 200 cells/mm3
only).

- Benzodiazepines within 14 days prior to study entry.

- Intralesional chemotherapy for Kaposi's sarcoma within 2 weeks prior to study entry.

- Therapy with antiretroviral drugs (including AZT, ddI, ddC, d4T) or investigational
drugs within 14 days prior to study entry.

Localized radiotherapy. Radiotherapy (other than localized). Active drug or alcohol abuse.